Dosimetry of 60/61/62/64Cu-ATSM: a hypoxia imaging agent for PET
- First Online:
- 356 Downloads
Cu-diacetyl-bis(N4-methylthiosemicarbazone (Cu-ATSM) is an effective marker for the delineation of hypoxic tissue. Dosimetry calculations by the established Medical Internal Radionuclide Dose (MIRD) approach were performed with both animal and patient data.
Human absorbed dose estimates extrapolated from rat data were based on the biodistribution of 61Cu-ATSM in adult rats. Eighteen tissues were harvested and time–activity curves generated. The measured residence times and the MIRD S-values for 60Cu-ATSM were used to estimate human absorbed doses. The biodistribution of the tracer was directly measured in five patients injected with approximately 480 MBq of 60Cu-ATSM and imaged by positron emission tomography (PET) with a whole-body protocol. The combined data from all patients were used to derive organ residence times, and organ doses were calculated by MIRD methodology for 60Cu-ATSM, 61Cu-ATSM, 62Cu-ATSM, and 64Cu-ATSM.
Human absorbed dose estimates extrapolated from rat biodistribution data indicated that the kidneys appeared to be the dose-limiting organ (0.083 mGy/MBq) with a whole-body dose of 0.009 mGy/MBq. Based on the human PET imaging data, the liver appeared as the dose-limiting organ, with an average radiation dose of 0.064 mGy/MBq. The whole-body dose was 0.009 mGy/MBq and the effective dose was 0.011 mSv/MBq.
These relatively small absorbed doses to normal organs allow for the safe injection of 500–800 MBq of 60Cu-ATSM, which is sufficient for PET imaging in clinical trials.
KeywordsRadiation dosimetry Positron emission tomography Hypoxia Biodistribution
- 1.Crabtree HG, Cramer W. The action of radium on cancer cells I and II. Some factors determining the susceptibility of cancer cells to radium. Proc R Soc Ser B 1933;113:238–50.Google Scholar
- 2.Brown JM. The hypoxic cell: A target for selective cancer therapy—Eighteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 1999;59:5863–70.Google Scholar
- 3.Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. Concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953;26:638–48.Google Scholar
- 4.Tannock I, Guttman P. Responses of Chinese hamster ovary cells to anticancer drugs under aerobic and hypoxic conditions. Br J Cancer 1981;42:245–8.Google Scholar
- 5.Lewis JS, Welch MJ. PET Imaging of hypoxia. Q J Nucl Med 2001;45:183–8.Google Scholar
- 8.Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997;38:1155–60.Google Scholar
- 9.Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ. Evaluation of 64Cu-ATSM in vivo and in vitro in a hypoxic tumor model. J Nucl Med 1999;40:177–83.Google Scholar
- 10.Lewis JS, Sharp TL, Laforest R, Fujibayashi Y, Welch MJ. Tumor uptake of copper-diacetyl-bis(N4-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med 2001;42:655–61.Google Scholar
- 13.Haynes NG, Lacy JL, Nayak N, Martin CS, Dai D, Mathias CJ, et al. Performance of a 62Zn/62Cu generator in clinical trials of PET perfusion agent 62Cu-PTSM. J Nucl Med 2000;41:309–14.Google Scholar
- 14.Fujibayashi Y, Matsumoto K, Yonekura Y, Konishi J, Yokoyama A. A new zinc-62/copper-62 generator as a copper-62 source for PET radiopharmaceuticals. J Nucl Med 1989;30:1838–42.Google Scholar
- 15.McCarthy DW, Shefer RE, Klinkowstein RE, Bass LA, Margeneau WH, Cutler CS, et al. Efficient production of high specific activity 64Cu using a biomedical cyclotron. Nucl Med Biol 1997;24:35–43.Google Scholar
- 16.McCarthy DW, Bass LA, Cutler PD, Shefer RE, Klinkowstein RE, Herrero P, et al. High purity production and potential applications of copper-60 and copper-61. Nucl Med Biol 1999;26:351–8.Google Scholar
- 17.National Nuclear Data Center, BrookHaven National Laboratory, http://www.nndc.bnl.gov/mird
- 18.Anderson CJ, Jones LA, Bass LA, Sherman EL, McCarthy DW, Cutler PD, et al. Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor bearing rats. J Nucl Med 1998;39:1944–51.Google Scholar
- 19.Lewis JS, Lewis MR, Cutler PD, Srinivasan A, Schmidt MA, Schwarz SW, et al. Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive, tumor bearing rat model. Clin Cancer Res 1999;5:3608–16.Google Scholar
- 20.Lewis JS, Laforest R, Lewis MR, Anderson CJ. Comparative dosimetry of copper-64 and yttrium-90-labeled somatostatin analogs in a tumor-bearing rat model. Cancer Biotherapy Radiopharm 2000;15:593–604.Google Scholar
- 22.Cutler PD, Schwarz SW, Anderson CJ, Connett JM, Welch MJ, Philpott GW, et al. Dosimetry of copper-64-labeled monoclonal antibody 1A3 as determined by PET imaging of the torso. J Nucl Med 1995;36:2363–71.Google Scholar
- 23.Recommendations of the International Commission on Radiological Protection, 1990.Google Scholar
- 24.Takahashi N, Fujibayashi Y, Yonekura Y, Welch MJ, Waki A, Tsuchida T, et al. Evaluation of 62Cu labeled diacetyl-bis(N4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer. Ann Nucl Med 2000;14:323–8.Google Scholar
- 25.Fritzberg AR, Bloedow DC. Animal models in the study of hepatobiliary radiotracers. In: Lambrecht RM, Eckelman WC, editors. Animal models in radiotracer design. Berlin Heidelberg New York: Springer; 1983. p. 179–209.Google Scholar